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Abstract 
Three series of arylbenzimidazole derivatives 3-40, 45 have been simply synthesized and tested for 
their antioxidant capacity. The 2-arylbenzimidazoles were tested against various radicals by the 
DPPH, FRAP and ORAC tests and showed different activity profiles. It has been observed that the 
number and position of the hydroxy groups on the 2-aryl portion and the presence of a diethylamino 
group or a 2-styryl group are related to a good antioxidant capacity. Furthermore, benzimidazoles 
showed satisfactory SPF values in vitro compared to the commercial PBSA filter, proving to have a 
good photoprotective profile. In particular, 2-arylbenzimidazole-5-sulphonic acids 15 and 38, the 2-
styryl-benzimidazole 45 showed broad spectrum solar protection against UVA and UVB rays.  The 
antiproliferative effect of the benzimidazoles was tested on human skin melanoma Colo-38 cells. 
The styrylbenzimidazole 45 exhibited antiproliferative effect at low micromolar concentration 
against Colo-38 cells and very low antiproliferative activity on normal HaCat keratinocyte cells.
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Graphical Abstract 
1. Introduction
Reactive oxygen (ROS) and nitrogen (NOS) species produced by metabolism of endogenous and 
exogenous substances led to oxidative stress. Clinical evidences account for the involvement of 
oxidative stress-induced by reactive oxygen and nitrogen species in a variety of disorders including 
cancer [1], atherosclerosis [2] neurodegeneration and aging [3]. ROS can be generated by UVB and 
UVA radiation producing protein oxidative modification resulting in photoaging.  ROS cause tissue 
modification that at skin level is elicited by the loss of the barrier function of the stratum corneum, 
the promotion of inflammatory processes, erythema, up to the cancer [4, 5]. The benzimidazole 
moiety represents a privileged structure in medicinal chemistry. Molecules of natural origin play a 
fundamental role in the research of bioactive molecular models for the development of new 
synthetic and semi-synthetic analogues. The discovery of 5,6-dimethyl-1-(D-ribofuranosil)-
benzimidazole, as an integral part of vitamin B12, has generated considerable interest in the 
benzimidazole nucleus [6]. This can be considered as a structural isostere of indole and purines, or 
other natural active substances capable of interacting with other biomolecules, such as proteins and 
nucleic acids [7]. 
Benzimidazole is a pharmacophore that has found widespread application in medicinal practice. The 
benzimidazole ring system exists in the structure of many drugs such as the antihypertensive 
Candesartan, the proton pump inhibitor Pantoprazole, the antihistaminic Astemizole, the 
antimicrobial Albendazole, analgesics, anti-inflammatories, anti-convulsant, anti-psychotic, anti-
diabetic, anthelmintic, antiprotozoal drugs and antifungals [8, 9]. Literature data also report a 
remarkable antiproliferative, anti-tumor, and antiviral biological activity [10] of the various 
derivatives of the benzimidazole nucleus. Furthermore, benzimidazole derivatives have been 
reported for their antioxidant activity [11-14].
The benzimidazole core also appears in some sunscreens; it is contained, for example, in 2-phenyl-
1H-benzimidazole-5-sulfonic acid (PBSA), one of the UVB filters mostly used in cosmetics for sun 
protection. PBSA is characterized by high water solubility in and has an excellent safety profile. 
Another effective example is the disodium salt of phenyl-dibenzimidazole-tetrasulfonate (known as 
Neo Heliopan® AP) which absorbs mainly in the UVA range. Neo Heliopan® AP is soluble in aqueous 
phase when added with a base, it is stable and safe, with an extremely low degree of penetration of 
the skin. In this context, a molecule was designed and synthesized with the aim of combining the 
filtering capacity of the already known PBSA and the strong antioxidant properties of polyphenols. 
The final product, called Oxisol (2-(3,4-dihydroxy-phenyl)-1H-benzimidazole-5-carboxylic acid), is 
not only a powerful antioxidant and absorbs in the UVA range, but is also equipped with SPF booster 
effect [15-16]. As a continuation of our efforts to identify dualistic molecules [17, 18] able to act, at 
the same time, as antioxidant and photoprotective agents here we describe the design, synthesis 
and biological evaluation of three series of benzimidazoles differing for the substituent at 5-position 
and bearing a variety of hydroxyaryl moieties at 2-position.
2. Results and Discussion
2.1. Chemistry
The target benzimidazoles 3–40, 45 (Table 1) were synthesized as shown in Schemes 1 and 2 starting 
from readily available and inexpensive starting materials.  The ethanolic solution of 
diaminobenzenes 1a-d was added with sodium metabisulphite aqueous solution and the 
appropriate aldehyde 2. The resulting solution was refluxed to achieve benzimidazoles (3-40) in 52-
88% yields (Scheme 1). Benzimidazole 45 was obtained following the reaction sequence showed in 
Scheme 2. 4-Hydroxycinnamic acid (41) was coupled with methyl 3,4-diaminobenzoate (42) in the 
presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and hydroxybenzotriazole 
(HOBt) in anhydrous acetonitrile solution to give the intermediate 43. Benzimidazole ring closure 
was performed in hydrochloric acid to give the ester derivative 44. Compound 44 was submitted to 
mild basic hydrolysis to afford the benzimidazole (45). Structures of all new compounds were 
confirmed based on analytical and spectral data which are consistent with results of reported 
studies [15, 19-21]
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Scheme 2. Reagents and conditions: i) EDC, HOBt, MeCN, r.t. 36 H; ii) EtOH, 6 N HCl, reflux 5 h; iii) EtOH, 2.5 
N NaOH, r.t. 24h.
2.2 Antioxidant activity
The valuation of the antioxidant properties of the benzimidazoles 3–40, 45 was achieved by 1,1-
diphenyl-2-picrylhydrazyl radical scavenging activity (DPPH), Ferric Reducing Antioxidant Power 
(FRAP), and Oxygen radical absorbance capacity (ORAC) methods. Results are shown in Table 1 and 
are expressed as μmolTE/g for DPPH, FRAP, and ORAC tests. For the best interpretation of the results 
of the DPPH, each compound was tested at the concentration capable of inhibiting 50% of the 
radical. However, in some cases it was not possible to obtain data reflecting 50% inhibition, even if 
the tested compounds are all in the standard calibration line.
DPPH result analysis indicated that high antioxidant capacity is correlated to high number of hydroxy 
groups present on the aryl ring at the 2-position. Benzimidazole derivatives 3–11 bearing a single 
hydroxy group on the aryl ring showed weak activity independently from the substituent present at 
5-position. The introduction of a second (compounds 13-17) or a third hydroxy group (compounds 
31-36) led to the best compounds of the series. Nevertheless, the hydroxy group position also 
affects antioxidant activity: in fact, 2,5-dihydroxybenzimidazole derivatives 13, 14 were about 2 
times more active than the 3,4-dihydroxyphenyl analogs 16, 17. While the shift of the 3-OH of 
compound 16 into 2-position to give the analog 12 produced drop in activity. Furthermore, the 
2,3,4-trihydroxyphenyl derivatives 31 and 32 were more active than the 2,4,6-trihydroxyphenyl 
analogs 34 and 35. On the contrary the comparison of the 5-sulfonyl substituted benzimidazoles 
indicated that the 2,4,6-trihydroxyphenyl analog 36 was characterized by antioxidant activity better 
than the corresponding 2,3,4-trihydroxyphenyl derivative 33. The replacement of one hydroxy 
group with an alkoxy group (compounds 18-24) or halogen atoms (compounds 25-30) led to 
reduction in activity. The introduction of a 4-diethylamino group (benzimidazoles 37 and 38) 
produced increase in activity as compared to compounds 7 and 8. 
On FRAP analysis, according to the results obtained from the DPPH test the most powerful 
derivatives were benzimidazoles 13-17 and 31-37. Interestingly, the 2-hydroxy-3-ethoxyphenyl 
derivatives 21, 22, the 2-hydroxy-4-(diethyl)amino derivatives 38, and  the 4-hydroxystyryl 
derivative 45 demonstrated good activity.
The compounds that showed the most interesting profile following the DPPH and FRAP tests were 
also subjected to a further test (ORAC) to determine their complete antioxidant activity profile. The 
4-hydroxy-styryl derivative 45 demonstrated the best antioxidant capacity. The 2-hydroxy-4-
(diethyl)aminophenyl derivatives 37 and 38 demonstrated high antioxidant capacity.  Contrary to 
DPPH and FRAP assays, in ORAC test the 2,3,4-trihydroxyphenyl derivative 31 showed better activity 
as compared to the corresponding 2,4,6-trihydroxyphenyl analog 34. The 5-COOH-benzimidazole 
derivatives (32, 35) and 5-SO3H-benzimidazole (33, 36) analogs displayed a reverse trend in ORAC 
antioxidant results.
Table 1. Antioxidant activity of the indole derivatives 3-40 and 45.
R
N
H
N
R1 R2
R3
R4R5
Compound
R R1 R2 R3 R4 R5 DPPHa
µmolTE/g
FRAPa
µmolTE/g
ORACa
µmolTE/g
3 H H H OH H H 10.9 ±1.5 15.1 ± 0.4 -
4 CN H H OH H H <15.8 b 30.3 ± 2.7 -
5 COOH H H OH H H < 39.2 b 94.2 ± 2.5 -
6 SO3H H H OH H H no activity c 24.6 ± 1.8 -
7 COOH OH H H H H 51.8 ± 0.6 103.3 ± 3.7 -
8 SO3H OH H H H H no activity c 187.4 ± 4.9 -
9 CN H OH H H H <18.3 b 29.0 ± 2.5 -
10 COOH H OH H H H 87.4 ± 1.2 223.4 ± 3.8 -
11 SO3H H OH H H H no activityc 56.5 ± 1.2 -
12 CN OH H OH H H <27.5 b 209.2 ± 1.8 -
13  CN OH H H OH H 4747.2 ± 19.9 10109.0 ± 13.7 20827.9 ± 29.5
14  COOH OH H H OH H 4824.7 ± 11.6 10318.2 ± 15.8 18378.7 ± 18.4
15 SO3H OH H H OH H 515.7 ± 1.8 1562.7 ± 13.1 16014.2 ± 67.4
16 CN H OH OH H H 2042.1 ± 7.3 6353.8 ± 11.6 8210.2 ± 25.0
17 COOH H OH OH H H 1946.8 ± 8.1 5502.3 ± 13.2 13536.6± 15.6
18 CN H OH OMe H H 39.9 ± 0.9 72.7 ± 3.3 -
19 COOH H OH OMe H H 48.4 ± 3.5 70.1 ± 2.3 -
20 SO3H H OH OMe H H no activity c 814.9 ± 5.8 -
21 COOH OH OEt H H H 109.7 ± 0.4 4098.7 ± 16.3 7639.9 ± 25.9
22 SO3H OH OEt H H H < 50.9 b 2556.6 ± 17.6 13900.6 ± 61.4
23 COOH OH H OMe H H 41.2 ± 2.4 113.5 ± 5.1 -
24 SO3H OH H OMe H H no activity c 27.7 ± 2.4 -
25 CN OH H H Cl H 45.0 ± 1.8 64.7 ± 3.9 -
26 COOH OH H H Cl H 81.6 ± 3.4 94.2 ± 2.5 -
27 SO3H OH H H Cl H << 59.6 b 174.7 ± 6.2 -
28 CN OH H H Br H 48.7 ± 1.7 48.5 ± 1.5 -
29 COOH OH H H Br H 81.3 ± 0.9 117.3 ± 4.1 -
30 SO3H OH H H Br H << 50.0 b 63.4 ± 2.7 -
31 CN OH OH OH H H 7112.7 ± 15.1 12049.2 ± 19.2 8312.9 ± 31.8
32 COOH OH OH OH H H 5026.6 ± 13.9 11375. ± 19.6 7321. ± 17.8
33 SO3H OH OH OH H H 1324.1 ± 14.2 9097.5 ± 16.7 6726.9 ± 17.4
34 CN OH H OH H OH 1473.0 ± 10.3 7138.2 ± 12.4 4758.0 ± 13.7
35 COOH OH H OH H OH 897.3 ± 5.6 2334.8 ± 7.5 9467.8 ± 63.2
36 SO3H OH H OH H OH 5026.6 ± 13.8 1970.3 ± 3 8679.5 ± 28.0
37 COOH OH H N(Et)2 H H 165.1 ± 7.5 5233.1 ± 6.2 14583.9 ± 110.0
38 SO3H OH H N(Et)2 H H 84.9 ± 0.7 925.7 ± 8.8 12871.7 ± 35.6
39 COOH 2-OH-naphthyl < 27.6 b 187.7 ± 3.1 -
40 SO3H 2-OH-naphthyl 4.9 ± 0.7 527.7± 8.8 4297.5 ± 41.5
45 COOH 4-OH-styryl 31.33 ± 0.7 792.0 ± 5.0 24852.0 ± 28.5
a Each value was obtained from three experiments (mean ± SE).
b LOQ limit of quantification; – not tested.
c precipitation of the compound is observed.
2.3 Evaluation of filtering parameters
On the benzimidazoles 13-17, 21, 22, 31-38, 40 and 45 endowed with the best antioxidant profile, 
in vitro tests were performed to determine the parameters fundamental for the evaluation of the 
filtering power: critical wavelength (λc) and SPF (Sun Protection Factor) and results are reported in 
Table 2. The Solar Protection Effectiveness Evaluation System specifies a SPF primarily representing 
a measure of UVB protection [22] is related to the UV absorption of substances. The UV spectra of 
the compounds 13-17, 21, 22, 31-38, 40 and 45 were recorded between 290 and 400 nm and 
compared with the commercial filter PBSA used as a reference UVB filter (λmax 302 nm). The 
superimposed UV spectra of the analyzed compounds were subdivided according to kind of 
substituent at 5-position (Figures 1-3). The UV absorption spectra of 5-cyanobenzidimidazoles 13, 
16, 31 and 34 (Figure 1) showed λmax shifted towards longer wavelengths as compared to the 
reference PBSA. Compound 13 showed the λmax closest to PBSA; however, its absorption range was 
the widest in the series with an absorbance reaching zero near 400 nm. The bathochromic shift is 
correlated to the increase in the number of hydroxy groups on the 2-aryl ring: the wavelength of 
maximum absorption was in fact greater for derivatives 31 and 34, both bearing three hydroxy 
groups. As can be seen from Figure 2, 5-carboxylic acid benzimidazole derivatives 14, 17, 21, 32, 35, 
37 and 45 were also characterized by a wide range of absorption which is exhausted well over 400 
nm. The spectral profile of benzimidazoles 37 and 45 was characterized by λmax shifted to 
wavelengths higher than 350 nm. However, all the 5-carboxylic acid benzimidazole derivatives 
displayed absorption spectra better than PBSA.
The profile of the UV spectra of the 5-sulfonic acid benzimidazole derivatives 15, 22, 33, 36, 38, and 
40 (Figure 3) was again wider than the reference, furthermore the λmax were greater than PBSA. 
The bathochromic shift appeared particularly evident for compound 38: once again, the presence 
of a tertiary amino group on the aromatic ring promotes the shift of the maximum absorption peak 
to the right in the spectrum.
Figure 1. UV absorption spectra of 5-cyano-2-arylbenzimidazole derivatives 13 (fuchsia), 16 (green), 31 (blue), 34 (red).
Figure 2. UV absorption spectra of the 5-carboxylic acid benzimidazole derivatives 14 (red), 17 (blue), 21 (yellow), 32 
(light green), 35 (blue), 37 (brown), 45 (pink).
Figure 3. UV absorption spectra of the 5-sulfonic acid benzimidazole derivatives 15 (yellow), 22 (purple), 33 (blue), 36 
(green), 38 (fuchsia), 40 (red). 
A preliminary in vitro study was carried out on the filtering properties to determine the UV 
protection potential of benzimidazoles 13-17, 21, 22, 31-38, 40 and 45. To date there is an approved 
and standardized method for in vitro assessment of UVA protection present in ISO 24443: 2012, 
however for the evaluation of UVB protection there is still no approved in vitro method. The method 
proposed by Diffey-Robson for the in vitro evaluation of the SPF parameter in 1989 [23] is still 
applied. The UV absorption spectra of the benzimidazoles 13-17, 21, 22, 31-38, 40 and 45 as well as 
the reference PBSA were recorded and the values relating to the filtering parameters were 
extrapolated (Table 2). According to the EU recommendation on the efficacy of sun protection 
products (2006/247/EC) a broad-spectrum solar product, capable of protecting the skin 
simultaneously from UVA and UVB rays, should have a λc value greater than 370 nm. On this 
criterion, the only interesting compounds of the 2-aryl-benzimidazole series were derivatives 15 and 
38 bearing a sulfonic acid moiety and the 2-styryl-benzimidazole 45. Another parameter that 
provides indications on the best blocked UV region is the UVA/UVB absorbance ratio. As defined by 
the aforementioned EU recommendation (2006/247 / EC), this ratio should be worth at least 1/3. 
Almost all the compounds belonging to the three series satisfied this requirement, most of them 
with values greater than 1, to indicate an absorption mainly in the UVA region.
Finally, the value of UVAPF0 was determined in relation to the guidelines provided by ISO-24443: all 
the above-mentioned polyhydroxylated compounds, which meet the effectiveness requirements 
imposed by EU legislation, have a better UVA Protection Factor than the reference commercial filter. 
The most interesting data were showed by compounds 37 and 38, with a UVAPF0 value of 14.30 
and 15.77 respectively.
Table 2. UV-filtering activity of selected benzimidazoles in solution.
Compound SPF UVA/UVB UVAPF0 c (nm) Compound SPF UVA/UVB UVAPF0 c (nm)
PBSA 3,4 0,29 1,03 322 32 2,71 1,04 1,51 348
13 2,93 0,73 2,28 369 33 1,70 0,81 1,10 343
14 2,79 0,75 2,19 368 34 3,34 1,27 1,78 349
15 2,55 0,70 2,06 373 35 3,20 0,90 1,49 355
16 4,63 0,86 1,79 350 36 4,96 0,67 1,58 350
17 4,26 0,85 1,71 349 37 1,79 2,10 14,30 387
21 6,03 0,37 1,39 342 38 1,71 2,20 15,77 386
22 6,25 0,29 1,32 340 40 2,3 0,77 1,62 362
31 2,56 1,10 1,48 347 45 2,42 2,27 7,86 384
2.4 In vitro release study of topical formulations
In analogy with one of our previously reported studies [18], we selected the most promising 
candidate in terms of antioxidant capacity and UV-filtering profile, compound 15, to assess its 
potential as an active ingredient of topical formulations in vitro. Therefore, the formulation 
conceived and designed for Oxisol [15], a molecule with dualistic activity, has been optimized for 
compound 15. Two topical formulations were then prepared with different degrees of polarity on 
the basis of the structures of the two compounds: Formulation (A) to obtain a high release of the 
active substance that carries out activity after absorption in the skin (active acting as an antioxidant) 
and the Formulation (B) to obtain a limited release, through a better solubilization of the active 
principle in the formulation (active that acts as a solar filter). The release of the two ingredients 
from the topical formulations was evaluated through the Franz cell system. The Franz cells consist 
of two vertical chambers (donor and acceptor) separated by a synthetic or biological membrane 
which has both the support function and the means of separation between the receiving medium 
and the formulation for which the release is to be studied. In this study, both for compound 15 and 
for Oxisol, the receptor phase was sampled within 6 hours to measure the quantity in the receiving 
chamber, the resulting release curves are reported in Figure 4. It was observed a 0.8% and 7% 
difference between the release curves of the two different formulations that characterize Oxisol 
and compound 15. Specifically, the two curves maintained the same trend as regards Oxisol, with a 
reduction in the delta after 240 minutes. With regard to derivative 15, in the first 30 minutes the 
same release could be observed from formulations A and B, but in later times the gap between the 
two curves tends to increase until it reached a difference of 7%. These results, like those obtained 
previously [18], confirm that it is possible, only by varying the components percentages in the 
formulation, to modify the release of the active ingredient. This approach therefore consists of 
modifying the polarity of a formulation on the basis of both the activity and the end use of the 
chosen active ingredient.
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Figure 4. Permeation profiles of Oxisol, and benzimidazole 15. Line blue corresponds to formulation A (optimized for 
skin adsorption), line orange corresponds to Formulation B (optimized to best solubilize the active in formula).
2.5 Antiproliferative activity on Human melanoma Colo38 cell line
The benzimidazoles 13-17, 21, 22, 31-38, 40 and 45 were tested on human melanoma Colo38 cell 
line to determine their antiproliferative activity. All the compounds have been tested on the cell line 
to evaluate the relative IC50 values expressed in μM concentration (Table 3). Benzimidazole 45 
exhibited the best activity of the series, displaying an antiproliferative effect at low micromolar 
concentration (IC50 values 6.20±0.22). The 2,3,4-trihydroxyphenyl derivatives 31-33 showed 
antiproliferative activity at micromolar concentration. On the contrary their 2,4,6-trihydroxyphenyl 
analogs (34-36) showed very poor antiproliferative effects or total inactivity at the used 
concentrations. Furthermore the 2,5-dihydrophenyl derivatives 13 and 15 inhibited the Colo38 cell 
growth at micromolar concentrations. 
Table 3. Effects of selected benzimidazole derivatives on the proliferation of Colo38 cells.
Compound IC50 (M) Compound IC50 (M)
13 50.14±2.41 33 74.4±6.27
14 409.31±4.44 34 446.96±33.71
15 79.13±10.21 35 > 500
16 62.02±7.76 36 > 500
17 424.53±44.47 37 171.84±38.24
21 318.06±40.49 38 450.79±41.32
22 > 500 40 323.78±22
31 96.23±10.25 45 6.20±0.22
32 65.07±0.18
2.6 Antiproliferative activity on human keratinocyte HaCat cell line
The benzimidazoles 13 and 45, demonstrating the best antiproliferative activity (IC50 values: 
50.14±2.41 and 6.20±0.22, respectively) on the melanoma Colo38 cells, were also tested on normal 
human keratinocyte HaCat cell line to preliminary evaluate their selectivity against cancer cells. Both 
compounds 13 and 45 showed low activity against HaCat cells (IC50 values: 278.97±48.01 µM and 
32.72±8.54 µM, respectively) being about 5-fold more active against Colo38 cell line. These results 
suggest a preferential activity of tested compounds against cancer cells.
3. Conclusion
A series of 2-arylbenzimidazole derivatives were synthesized with the aim to obtaining molecules 
with a dualistic functional profile, specifically in the context of multiprotective agents able to act 
both against the damage caused by the sun radiations exposure and by the oxidative stress 
promoted by free radicals.
All the synthesized benzimidazole derivatives 3–40, 45 were tested to evaluate their antioxidant 
profile with the DPPH and FRAP methods. The antioxidant activity profile was completed with the 
ORAC method only for the compounds that emerged as the best from the two above-mentioned 
tests. In general, it has been observed that the presence of a sulfonic acid group at 5-position of the 
benzimidazole nucleus is the least favourable, while the derivatives bearing a 5-cyano or 5-carboxyl 
acid groups have showed medium to high antioxidant activity.
The best antioxidant compounds were investigated for their UV-filtering activity showing 
heterogeneous profiles. Compounds 15, 38 (bearing a sulfonic acid group), and the 2-styryl-
benzimidazole 45 were the best in terms of broad spectrum filtering activity. All the analyzed 
benzimidazoles showed a better UVAPF0 value than the reference PBSA. The derivative 15 
maintained its filtering profile even when incorporated into formulations for topical use and might 
be chosen as a lead compound for further development. Thus, its release was evaluated from two 
different formulations designed ad hoc, varying the composition only, to optimize the skin 
absorption or the solubility of the active compound to promote application of the formulations as 
an antioxidant or sun filter. Furthermore, the investigation on the antiproliferative activity on 
human melanoma Colo38 cells showed compound 45 as the best in the series with an IC50 value at 
low micromolar concentrations level. The same compound inhibited the growth of normal HaCat 
keratinocytes at higher concentrations demonstrating an interesting selectivity against cancer cells. 
The overall results obtained from this study have pointed out the key role played by the arylhydroxy 
group in the benzimidazole ring which led to compounds endowed with multifunctional profile, 
more specifically marked in antioxidant and UV filtering activity such us 15 and 45 that constitute 
interesting lead compounds.
4. Experimental section
4.1 General methods.
All commercially available solvents and reagents were used without further purification. Standard 
samples were purchased from Sigma-Aldrich, Milan, Italy. NMR spectra were recorded on an Inova 
500 spectrometer (Varian, Palo Alto, CA, USA). The chemical shifts (δ) are reported in part per million 
downfield from tetramethylsilane (TMS), which was used as internal standard, and the spectra were 
recorded in hexadeuteriodimethylsulphoxide (DMSO‑d6). Infrared spectra were recorded on a 
Vector 22 spectrometer (Bruker, Bremen, Germany) in Nujol mulls. The main bands are given in cm-
1. Positive-ion electrospray ionization (ESI) mass spectra were recorded on a double-focusing MAT 
95 instrument (Finnigan, Waltham, MA, USA) with BE geometry. Melting points (mp) were 
determined on a SMP1 Melting Point apparatus (Stuart Scientific, Stone, UK) and are uncorrected. 
All products reported showed NMR spectra in agreement with the assigned structures. The purity 
of the tested compounds was determined by combustion
elemental analyses conducted by the Microanalytical Laboratory of the Chemistry Department of 
the University of Ferrara with a MT-5 CHN recorder elemental analyzer (Yanagimoto, Kyoto, Japan) 
and the values found were within 0.4% of theoretical values. The spectrophotometer used for 
antioxidant analysis is a Beckman Coulter™, DU®530, Life Science UV/VIS spectrophotometer, Single 
Cell Module. The instrument used to conduct ORAC analyzes is the Thermo Fluoroskan Ascent FL® 
Microplate Fluorometer and Luminometer, linked to Ascent Software® software for data control 
and processing. In the sample loading phase, 96-well plates with a black background were used. 
Spectrophotometric analysis for the detection of filter parameters were conducted with a UV–VIS 
spectrophotometer SHIMADZU UV-2600 240 V.
4.2. Chemistry
4.2.1. General procedure for the synthesis of benzimidazoles (3-40)
To a solution of the appropriate 3,4-diaminobenzene derivative (1a-d) (2 mmol) in ethanol (15 mL) 
2.85 N aqueous solution of sodium metabisulphite (1.6 mL) and the appropriate substituted 
arylaldehyde (2 mmol) were added. The reaction mixture was heated at reflux for 24 h. The solvent 
was then evaporated under reduced pressure. The residue was added with HCl 1N (10 mL), the 
formed precipitate was filtered off, washed with water (3 x 10 mL) and purified by crystallization 
from the adequate solvent to give the title compounds. Following the general procedure 
benzimidazoles 3 [19], 4 [20], 5 [21], 7 [24], 6, 32 and 33 [15] were prepared and their analytical and 
spectral data are in agreement with those reported in literature.
4.2.1.1. 2-(3-Hydroxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (9). Yield 80%. Mp >250 °C (EtOH). 
1H NMR (DMSO-d6): δ 7.08 (d, J = 8.0 Hz, 1H, Ar), 7.42 (t, J = 8.0 Hz, 1H, Ar), 7.64-7.70 (m, 3H, Ar), 
7.81 (d, J = 8.5Hz, 1H, BIM), 8.19 (s, 1H, BIM). IR (Nujol) 2227, 1589 cm-1. m/z 236 (M + H)+. Anal. 
Calcd for C14H9N3O: C, 71.48; H, 3.86; N, 17.86. Found: C, 71.41; H, 3.87; N, 17.90.
4.2.1.2. 2-(3-Hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (10). Yield 62%. Mp 208-210 °C 
(EtOH). 1H NMR (DMSO-d6): δ 7.03 (d, J = 7.5 Hz, 1H, Ar), 7.44 (t, J = 8.0 Hz, 1H, Ar), 7.64 (m, 2H, Ar), 
7.74 (d, J = 8.5Hz, 1H, BIM), 7.94 (d, J = 8.0 Hz, 1H, BIM), 8.23 (s, 1H, BIM), 9.96 (s, 1H, OH). IR (Nujol) 
3360, 2726, 1693, 1569 cm-1. m/z 255 (M + H)+. Anal. Calcd for C14H10N2O3: C, 66.14; H, 3.96; N, 
11.02. Found: C, 66.09; H, 3.98; N, 11.05.
4.2.1.3. 2-(3-Hydroxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (11). Yield 69%. Mp 219-220 °C 
(EtOH). 1H NMR (DMSO-d6): δ 7.16 (d, J = 8.0 Hz, 1H, Ar), 7.53 (d, J = 8.0 Hz, 1H, Ar), 7.57 (s, 1H, Ar), 
7.62 (d,  J = 8.0 Hz, 1H, Ar), 7.77 (d, J = 8.0 Hz, 1H, Ar), 7.82 (d, J = 8.5 Hz, 1H, Ar), 9.96 (s, 1H, Ar), 
10.23 (s, 1H, OH). IR (Nujol) 3397, 3274, 1631, 1588 cm-1. m/z 291 (M + H)+. Anal. Calcd for 
C13H10N2O4S: C, 53.79; H, 3.47; N, 9.65. Found: C, 53.84; H, 3.46; N, 9.68. 
4.2.1.4. 2-(2,4-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (12). Yield 63%. Mp 233-234 
°C (EtOH). 1H NMR (DMSO-d6): δ 6.56 (d, J = 8.5 Hz, 1H, Ar), 6.68 (s, 1H, Ar), 7.81 (d, J = 8.0 Hz, 1H, 
BIM), 7.89 (d, J = 8.0 Hz, 1H, BIM), 8.05 (d, J = 8.5 Hz, 1H, Ar), 8.20 (s, 1H, BIM). IR (Nujol) 3348, 3211, 
3086, 2242, 1611 cm-1. m/z 252 (M + H)+. Anal. Calcd for C14H9N3O2: C, 66.93; H, 3.61; N, 16.73. 
Found: C, 66.99; H, 3.60; N, 16.70.
4.2.1.5. 2-(2,5-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (13). Yield 78%. Mp >250 °C 
(EtOH). 1H NMR (DMSO-d6): δ 6.98 (s, 2H, Ar), 7.50 (s, 1H, Ar), 7.73 (d, J = 8.0 Hz, 1H, BIM), 7.86 (d, 
J = 8.5 Hz, 1H, BIM), 8.21 (s, 1H, BIM). 13C (DMSO-d6): δ 108.2, 112.6, 116.6, 121.1 (2C), 125.6 (2C), 
128.9, 130.3, 135.7, 138.9, 141.8, 147.1, 148.1.  IR (Nujol) 2230, 1617, 1564 cm-1. m/z 252 (M + H)+. 
Anal. Calcd for C14H9N3O2: C, 66.93; H, 3.61; N, 16.73. Found: C, 66.87; H, 3.63; N, 16.77.
4.2.1.6. 2-(2,5-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (14). Yield 65%. Mp >250 
°C (EtOH). 1H NMR (DMSO-d6): δ 6.99 (s, 2H, Ar), 7.47 (s, 1H, Ar), 7.81 (d, J = 8.0Hz, 1H, BIM), 7.99 
(d, J = 8.5Hz, 1H, BIM), 8.31 (s, 1H, BIM), 9.40 brs (1H, OH); 13C (DMSO-d6): δ 113.2, 116.4 (2C), 119.8 
(2C), 120.5 (2C), 132.7, 139.2, 142.6, 145.7 , 152.0, 154.2, 153.9.  IR (Nujol) 31.84, 2720, 1718, 1620 
cm-1. m/z 271 (M + H)+. Anal. Calcd for C14H10N2O4: C, 62.22; H, 3.73; N, 10.37. Found: C, 62.28; H, 
3.71; N, 10.34.
4.2.1.7. 2-(2,5-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (15). Yield 71%. Mp >250 °C 
(EtOH). 1H NMR (DMSO-d6): δ 7.04 (s, 2H, Ar), 7.43 (s, 1H, Ar), 7.75 (s, 2H, Ar), 8.02 (s, 1H, Ar), 9.41 
(s, 1H, NH). IR (Nujol) 3392, 3225, 3097, 1633, 1569 cm-1. m/z 307 (M + H)+. Anal. Calcd for 
C13H10N2O5S: C, 50.98; H, 3.29; N, 9.15. Found: C, 50.94; H, 3.31; N, 9.18.
4.2.1.8. 2-(3,4-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (16). Yield 75%. Mp >250 °C 
(EtOH). 1H NMR (DMSO-d6): δ 7.04 (d, J = 8.5 Hz, 1H, Ar), 7.65 (s, 1H, Ar), 7.67 (d, J = 8. 5 Hz, 1H, Ar), 
7.79 (d, J = 8.5 Hz, 1H, BIM), 7.85 (d, J = 8.0 Hz, 1H, BIM), 8.21 (s, 1H, BIM). IR (Nujol) 3428, 3331, 
3105, 2242, 1611 cm-1. m/z 252 (M + H)+. Anal. Calcd for C14H9N3O2: C, 66.93; H, 3.61; N, 16.73. 
Found: C, 66.85; H, 3.59; N, 16.70.
4.2.1.9. 2-(3,4-Dihydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (17). Yield 81%. Mp 224-
226 °C (EtOH). 1H NMR (DMSO-d6): δ 7.04 (d, J = 8.5 Hz, 1H, Ar), 7.67 (d, J = 9.0 Hz, 1H, Ar), 7.69 (s, 
1H, Ar), 7.78 (d, J = 8.5 Hz, 1H, BIM), 8.01 (d, J = 8.0 Hz, 1H, BIM), 8.23 (s, 1H, BIM), 9.50 (brs, 1H, 
OH). IR (Nujol) 3317, 2760, 1694, 1603, 1524 cm-1. m/z 271 (M + H)+. Anal. Calcd for C14H10N2O4: C, 
62.22; H, 3.73; N, 10.37. Found: C, 62.16; H, 3.74; N, 10.40.
4.2.1.10. 2-(3-Hydroxy-4-methoxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (18). Yield 58%. Mp 
>250 °C (EtOH). 1H NMR (DMSO-d6): δ 3.81 (s, 3H, OCH3), 6.66-6.68 (m, 2H, Ar), 7.73 (d, J = 8.0 Hz, 
1H, BIM), 7.83 (d, J = 8.5 Hz, 1H, BIM), 8.06 (d, J = 8.5Hz, 1H, Ar), 8.15 (s, 1H, BIM). IR (Nujol) 2228, 
1618 cm-1. m/z 266 (M + H)+. Anal. Calcd for C15H11N3O2: C, 67.92; H, 4.18; N, 15.84. Found: C, 67.98; 
H, 4.20; N, 15.80.
4.2.1.11. 2-(3-Hydroxy-4-methoxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (19). Yield 60%. 
Mp 223-234 °C (EtOH). 1H NMR (DMSO-d6): δ 3.83 (s, 3H, OCH3), 6.72 (s, 2H, Ar), 7.81 (d, J = 8.0 Hz, 
1H, Ar), 8.00 (d, J = 8.5 Hz, 1H, BIM), 8.08 (d, J = 9.5 Hz, 1H, BIM), 8.30 (s, 1H, BIM), 9.70 (brs, 1H, 
OH). IR (Nujol) 3293, 2725, 1697, 1626 cm-1. m/z 285 (M + H)+. Anal. Calcd for C15H12N2O4: C, 63.38; 
H, 4.25; N, 9.85. Found: C, 63.33; H, 4.27; N, 9.88.
4.2.1.12. 2-(3-Hydroxy-4-methoxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (20). Yield 69%. Mp 
>250 °C (EtOH). 1H NMR (DMSO-d6): δ 3.93 (s, 3H, OCH3), 7.30 (d, J = 8.5 Hz, 1H, Ar), 7.60 (s, 1H, Ar), 
7.68-7.68 (m, 2H, Ar and BIM), 7.79 (d, J = 9.0 Hz, 1H, BIM), 7.93 (s, 1H, BIM), 9.78 (s, 1H, OH). IR 
(Nujol) 3367, 3149, 3089, 2781, 1634, 1610, 1583 cm-1. m/z 321 (M + H)+. Anal. Calcd for 
C14H12N2O5S: C, 52.49; H, 3.78; N, 8.75. Found: C, 52.54; H, 3.77; N, 8.72.
4.2.1.13. 2-(3-Ethoxy-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (21). Yield 52%. Mp 
>250 °C (EtOH). 1H NMR (DMSO-d6): δ 1.37 (t, J = 7.0 Hz, 3H, CH3), 4.11 (q, J = 7.0 Hz, 2H, CH2), 6.98 
(t, J = 8.0 Hz, 1H, Ar), 7.15 (d, J = 8.0 Hz, 1H, Ar), 7.64 (d, J = 7.5 Hz, 1H, Ar), 7.77 (d, J = 8.0 Hz, 1H, 
BIM), 7.95 (d, J = 9.0 Hz, 1H, BIM), 8.27 (s, 1H, BIM). IR (Nujol) 3463, 3030, 2680, 1682, 1624, 1594 
cm-1. m/z 299 (M + H)+. Anal. Calcd for C16H14N2O4: C, 64.42; H, 4.73; N, 9.39. Found: C, 64.37; H, 
4.74; N, 9.43.
4.2.1.14. 2-(3-Ethoxy-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (22). Yield 56%. Mp 
236-237 °C (EtOH). 1H NMR (DMSO-d6): δ 1.40 (t, J = 6.5Hz, 3H, CH3), 4.21 (q, J = 6.5 Hz, 2H, CH2), 
7.08 (t, J = 8.0 Hz, 1H, Ar), 7.31 (d, J = 8.0 Hz, 1H, Ar), 7.59 (d, J = 8.0 Hz, 1H, Ar), 7.78 (d, J = 9.0 Hz, 
1H, BIM), 7.80 (d, J = 8.5Hz, 1H, BIM), 8.06 (s, 1H, BIM). IR (Nujol) 3448, 3227, 1625, 1561 cm-1. m/z 
335 (M + H)+. Anal. Calcd for C15H14N2O5S: C, 53.88; H, 4.22; N, 8.38. Found: C, 53.94; H, 4.24; N, 
8.34.
4.2.1.15. 2-(2-Hydroxy-4-methoxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (23). Yield 58%. 
Mp 219-220 °C (EtOH). 1H NMR (DMSO-d6): δ 3.80 (s, 3H, OCH3), 7.22 (d, J = 8.5 Hz, 1H, Ar), 7.65 (s, 
1H, Ar), 7.70 (d, J = 8.5 Hz, 1H, Ar), 7.76 (d, J = 8.0 Hz, 1H, BIM), 7.98 (d, J = 8.5 Hz, 1H, BIM), 8.22 (s, 
1H, BIM). IR (Nujol) 3447, 3130, 2766, 1713, 1615 cm-1. m/z 285 (M + H)+. Anal. Calcd for C15H12N2O4: 
C, 63.38; H, 4.25; N, 9.85. Found: C, 63.45; H, 4.23; N, 9.89.
4.2.1.15. 2-(2-Hydroxy-4-methoxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (24). Yield 59%. Mp 
226-227 °C (EtOH). 1H NMR (DMSO-d6): δ 3.87 (s, 3H, OCH3), 6.69 (s, 1H, Ar), 6.78 (m, 1H, Ar), 7.71 
(m, 2H, BIM), 7.98 (m, 1H, Ar), 8.02 (s, 1H, BIM). IR (Nujol) 3163, 1621, 1572 cm-1. m/z 321 (M + H)+. 
Anal. Calcd for C14H12N2O5S: C, 52.49; H, 3.78; N, 8.75. Found: C, 52.44; H, 3.80; N, 8.78.
4.2.1.16. 2-(5-Chloro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (25). Yield 83%. Mp 
200-202 °C (EtOH). 1H NMR (DMSO-d6): δ 7.16 (d, J= 9.0 Hz, 1H, Ar), 7.47 (d, J = 9.0 Hz, 1H, Ar), 7.71 
(d, J = 8.5 Hz, 1H, BIM), 7.86 (d, J = 8.5 Hz, 1H, BIM), 8.19 (s, 1H, Ar), 8.20 (s, 1H, BIM). IR (Nujol) 
3340, 3059, 2727, 2232, 1615 cm-1. m/z 270 (M + H)+. Anal. Calcd for C14H8ClN3O: C, 62.35; H, 2.99; 
N, 15.58. Found: C, 62.42; H, 2.98; N, 15.55.
4.2.1.17. 2-(5-Chloro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (26). Yield 82%. Mp 
203-204 °C (EtOH). 1H NMR (DMSO-d6): δ 7.14 (d, J = 8.5 Hz, 1H, Ar), 7.45 (d, J = 8.0 Hz, 1H, Ar), 7.78 
(d, J = 8.5 Hz, 1H, BIM), 7.95 (d, J = 8.5 Hz, 1H, BIM), 8.19 (s, 1H, Ar), 8.28 (s, 1H, BIM). IR (Nujol) 
3320, 3225, 3070, 2688, 1685, 1632, 1558 cm-1. m/z 289 (M + H)+. Anal. Calcd for C14H9ClN2O3: C, 
58.25; H, 3.14; N, 9.70. Found: C, 58.16; H, 3.15; N, 9.74.
4.2.1.18. 2-(5-Chloro-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (27). Yield 85%. Mp 
226-227 °C (EtOH). 1H NMR (DMSO-d6): δ 7.25 (d, J = 8.0 Hz, 1H, Ar), 7.61 (d, J = 8.0 Hz, 1H, Ar), 7.80 
(m, 2H, BIM and Ar), 8.06 (s, 1H, BIM), 8.20 (s, 1H, BIM). IR (Nujol) 3582, 3375, 3060, 2720, 1624, 
1556 cm-1. m/z 325 (M + H)+. Anal. Calcd for C13H9ClN2O4S: C, 48.08; H, 2.79; N, 8.63. Found: C, 48.03; 
H, 2.81; N, 8.67.
4.2.1.19. 2-(5-Bromo-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (28). Yield 85%. Mp 
215-216 °C (EtOH). 1H NMR (DMSO-d6): δ 7.12 (d, J = 9.0 Hz, 1H, Ar), 7.58 (d, J = 9.0 Hz, 1H, Ar), 7.72 
(d, J = 8.0 Hz, 1H, BIM), 7.86 (d, J = 8.5Hz, 1H, BIM), 8.20 (s, 1H, Ar), 8.31 (s, 1H, BIM). IR (Nujol) 2220, 
1607, 1552 cm-1. m/z 314 (M + H)+. Anal. Calcd for C14H8BrN3O: C, 53.53; H, 2.57; N, 13.38. Found: 
C, 53.49; H, 2.58; N, 13.41.
4.2.1.20. 2-(5-Bromo-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (29). Yield 84%. Mp 
233-235 °C (EtOH). 1H NMR (DMSO-d6): δ 7.09 (d, J = 8.5 Hz, 1H, Ar), 7.60 (d, J = 8.5 Hz, 1H, Ar), 7.78 
(d, J = 8.5 Hz, 1H, BIM), 7.95 (d, J = 8.5 Hz, 1H, BIM), 8.28 (s, 1H, Ar), 8.31 (s, 1H, BIM). IR (Nujol) 
3320, 3170, 2670, 1638, 1624, 1555 cm-1. m/z 332 (M + H)+. Anal. Calcd for C14H9BrN2O3: C, 50.47; 
H, 2.72; N, 8.41. Found: C, 50.53; H, 2.71; N, 8.44.
4.2.1.21. 2-(5-Bromo-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (30). Yield 88%. Mp 
240-241 °C (EtOH). 1H NMR (DMSO-d6): δ 7.16 (d, J = 9.0 Hz, 1H, Ar), 7.72 (d, J = 9.0 Hz, 1H, Ar), 7.79 
(m, 2H, BIM), 8.04 (s, 1H, Ar), 8.27 (s, 1H, BIM). IR (Nujol) 3350, 3264, 3199, 2722, 2670, 1625, 1605, 
1556 cm-1. m/z 368 (M + H)+. Anal. Calcd for C13H9BrN2O4S: C, 42.29; H, 2.46; N, 7.59. Found: C, 
42.24; H, 2.45; N, 7.62.
4.2.1.22. 2-(2,3,4-Trihydroxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (31). Yield 72%. Mp 232-
233 °C (EtOH). 1H NMR (DMSO-d6): δ 6.65 (d, J = 9.0 Hz, 1H, Ar), 7.60 (d, J = 8.5 Hz, 1H, Ar), 7.80 (d, 
J = 8.0 Hz, 1H, BIM), 7.88 (d, J = 8.0 Hz, 1H, BIM), 8.20 (s, 1H, BIM). IR (Nujol) 2228, 1619, 1571 cm-
1. m/z 267 (M + H)+. Anal. Calcd for C14H9N3O3: C, 62.92; H, 3.39; N, 15.72. Found: C, 62.85; H, 3.41; 
N, 15.76.
4.2.1.23. 2-(2,4,6-Trihydroxyphenyl)-1H-benzo[d]imidazole-5-carbonitrile (34). Yield 74%. Mp >250 
°C (EtOH). 1H NMR (DMSO-d6): δ 6.22 (s, 1H, Ar), 6.22 (s, 1H, Ar), 7.87 (d, J = 8.5Hz, 1H, BIM), 7.95 
(d, J = 8.5 Hz, 1H, BIM), 8.21 (s, 1H, BIM). IR (Nujol) 2230, 1625 cm-1. m/z 267 (M + H)+. Anal. Calcd 
for C14H9N3O3: C, 62.92; H, 3.39; N, 15.72. Found: C, 62.99; H, 3.38; N, 15.69.
4.2.1.24. 2-(2,4,6-Trihydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (35). Yield 75%. Mp 
>250 °C (EtOH). 1H NMR (DMSO-d6): δ 6.01 (s, 2H, Ar), 7.69 (d, J = 8.0 Hz, 1H, BIM), 7.83 (d, J = 8.5 
Hz, 1H, BIM), 8.26 (s, 1H, BIM), 13.19 (s, 1H, OH), 13.24 (s, 1H, OH). IR (Nujol) 3404, 3233, 2718, 
1704, 1614, 1565 cm-1. m/z 287 (M + H)+. Anal. Calcd for C14H10N2O5: C, 58.74; H, 3.52; N, 9.79. 
Found: C, 58.69; H, 3.50; N, 9.83.
4.2.1.25. 2-(2,4,6-Trihydroxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (36). Yield 75%. Mp 224-
225 °C (EtOH). 1H NMR (DMSO-d6): δ 6.14 (s, 2H, Ar), 7.70 (d, J = 8.5Hz, 1H, BIM), 7.74 (d, J = 8.5 Hz, 
1H, BIM), 8.11 (s, 1H, BIM), 10.45 (s, 1H, NH), 11, 80 (s, 2H, OH), 13,20 (s, 1H, OH). IR (Nujol) 3489, 
3216, 1629 cm-1. m/z 267 (M + H)+. Anal. Calcd for C13H10N2O6S: C, 48.45; H, 3.13; N, 8.69. Found: C, 
48.49; H, 3.11; N, 8.72.
4.2.1.26. 2-(4-(Diethylamino)-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-carboxylic acid (37). Yield 
59%. Mp 212-213 °C (EtOH). 1H NMR (DMSO-d6): δ 1.14 (t, J = 7.0 Hz, 6H, CH3), 3.41 (q, J = 7.0 Hz, 
4H, CH ), 6.30 (s, 1H, Ar), 6.47 (d, J = 9.0 Hz, 1H, Ar), 7.70 (d, J = 8.5 Hz, 1H, BIM), 7.85 (d, J = 8.5 Hz, 
1H, BIM), 7.94 (d, J = 8.0 Hz, 1H, Ar), 8.20 (s, 1H, BIM). 13C (DMSO-d6): δ 15.6 (2C), 52.1 (2C), 98.6, 
106.3, 108.2, 117.2 (2C), 121.3, 128.2 (2C), 131.8, 140.2, 145.2 (2C), 147.6, 163.3. IR (Nujol) 3446, 
3181, 2681, 1691, 1615 cm-1. m/z 326 (M + H)+. Anal. Calcd for C18H19N3O3: C, 66.45; H, 5.89; N, 
12.91. Found: C, 66.52; H, 5.86; N, 12.94.
4.2.1.27. 2-(4-(Diethylamino)-2-hydroxyphenyl)-1H-benzo[d]imidazole-5-sulfonic acid (38) Yield 
63%. Mp 221-222 °C (EtOH). 1H NMR (DMSO-d6): δ 1.16 (t, J = 7.0 Hz, 6H, CH3), 3.43 (q, J = 7.0 Hz, 
4H, CH2), 6.36 (s, 1H, Ar), 6.53 (d, J = 8.5 Hz, 1H, Ar), 7.65 (d, J = 8.5 Hz, 1H, BIM), 7.71 (d, J = 8.5 Hz, 
1H, BIM), 7.85 (d, J = 8.5 Hz, 1H, Ar), 7.97 (s, 1H, BIM), 11.42 (s, 1H, NH), 13.55 (s, 1H, OH). 13C 
(DMSO-d6): δ 14.1 (2C), 45.3 (2C), 100.3, 104.1, 110.8, 112.3, 115.6, 122.7, 133.2, 139.7, 143.7, 145.6 
(2C), 155.2, 157.5. IR (Nujol) 3442, 3321, 1613 cm-1. m/z 362 (M + H)+. Anal. Calcd for C17H19N3O4S: 
C, 56.50; H, 5.30; N, 11.63. Found: C, 56.45; H, 5.28; N, 11.67.
4.2.1.28. 2-(2-Hydroxynaphthalen-1-yl)-1H-benzo[d]imidazole-5-carboxylic acid (39). Yield 58%. Mp 
>250 °C (EtOH). 1H NMR (DMSO-d6): δ 7.42 (m, 2H, Ar), 7.54 (t, J = 8.5 Hz, 1H, Ar), 7.87 (d, J = 9.0 Hz, 
1H, BIM), 7.92-7.96 (m, 2H, Ar), 8.05 (d, J = 8.5 Hz, 1H, BIM), 8.10 (d, J = 8.5 Hz, 1H, Ar), 8.35 (s, 1H, 
BIM). IR (Nujol) 3463, 2680, 1682, 1624, 1594 cm-1. m/z 305 (M + H)+. Anal. Calcd for C18H12N2O3: C, 
71.05; H, 3.97; N, 9.21. Found: C, 70.98; H, 3.98; N, 9.25.
4.2.1.29. 2-(2-Hydroxynaphthalen-1-yl)-1H-benzo[d]imidazole-5-sulfonic acid (40). Yield 61%. Mp 
>250 °C (EtOH). 1H NMR (DMSO-d6): δ 7.43 (d, J = 9.0 Hz, 1H, Ar), 7.47 (t, J = 7.5 Hz, 1H, Ar), 7.57 (t, 
J = 8.0 Hz, 7.5Hz, 1H, Ar), 7.72 (d, J = 8.0 Hz, 1H, Ar), 7.83 (d, J = 9.0 Hz, 1H, Ar), 7.89 (d, J = 8.0 Hz, 
1H, Ar) 8.01 (d, J = 8.0 Hz, 1H, BIM), 8.04 (s, 1H, BIM), 8.18 (d, J = 8.5 Hz, 1H, BIM), 10.81 (s. 1H, OH). 
IR (Nujol) 3423, 1621, 1588 cm-1. m/z 341 (M + H)+. Anal. Calcd for C17H12N2O4S: C, 59.99; H, 3.55; N, 
8.23. Found: C, 60.05; H, 3.53; N, 8.26.
4.2.2. (E)-Methyl 4-amino-3-(3-(4-hydroxyphenyl)acrylamido)benzoate (43). 
A solution of 4-hydroxycinnamic acid (41) (0.33 g, 2 mmol), EDC (0.38 g, 2.2 mmol) and HOBt (0.26 
g, 2 mmol) in anhydrous MeCN (10 mL) was stirred at r.t. for 30 minutes, then methyl 3,4-
diaminobenzoate (42) (0.33 g, 2 mmol) was added. The mixture was stirred at r.t. After 36 h the 
solvent was removed in vacuum. The residue was dissolved in ethyl acetate (AcOEt) (20 mL) and 
washed sequentially with brine (2 x 5 mL), 10% citric acid (2 x 5 mL), saturated NaHCO3 aqueous 
solution (2 x 5 mL) and water (2 x 5 mL). The organic layer was dried over anhydrous Na2SO4 and 
evaporated under vacuum to give the title compound in 82% yield. Mp 174-176 °C (EtOH). 1H NMR 
(DMSO-d6): δ 3.76 (s, 3H, CH3), 5.81 (s, 2H, NH2), 6.67 (d, J = 16.0 Hz, 1H, CH), 6.76 (d, J = 8.0 Hz, 1H, 
Ar), 6.83 (d, J = 9.0 Hz, 2H, Ar), 7.46-7.55 (m, 5H, Ar and CH) 8.03 (s, 1H, Ar), 9.26 (s, 1H, NH), 9.92 
(s, 1H, OH). IR (Nujol) 3148, 1700, 1599 cm-1. m/z 313 (M + H)+. Anal. Calcd for C17H16N2O4: C, 65.38; 
H, 5.16; N, 8.97. Found: C, 65.32; H, 5.18; N, 9.00.
4.2.3. (E)-Methyl 2-(4-hydroxystyryl)-1H-benzo[d]imidazole-5-carboxylate (44). 
(E)-methyl 4-amino-3-(3-(4-hydroxyphenyl)acrylamido)benzoate (43) (0.70 g, 2.2 mmol) was 
dissolved in ethanol (1.5 mL) and then 6N aqueous hydrochloric acid solution (15 mL) was added. 
The mixture was heated at 100 °C for 5 h The ethanol was removed in vacuum and the residue 
cooled to 10° C. The formed precipitate was filtered off and air dried. Yield 74%. Mp 215-216 °C 
(EtOH). 1H NMR (DMSO-d6): δ 3.92 (s, 3H, CH3), 6.93 (d, J = 7.5 Hz, 2H, Ar), 7.09 (d, J = 15.5 Hz, 1H, 
CH), 7.61 (d, J = 7.5 Hz, 2H, Ar), 7.82 (s, 1H, Ar), 8.05 (m, 2H, Ar), 8.18 (d, J = 15.5 Hz, 1H, CH), 8.23 
(s, 1H, NH), 10.34 (s, 1H, OH).  IR (Nujol)3453, 3223, 1621, 1588 cm-1. m/z 295 (M + H)+. Anal. Calcd 
for C17H14N2O3: C, 69.38; H, 4.79; N, 9.52. Found: C, 69.43; H, 4.76; N, 9.56.
4.2.4. (E)-2-(4-hydroxystyryl)-1H-benzo[d]imidazole-5-carboxylic acid (45). 
To a solution of (E)-methyl 2-(4-hydroxystyryl)-1H-benzo[d]imidazole-5-carboxylate (44) (0.36 g, 
1.22 mmol) in ethanol (5 mL) 2.5N aqueous solution sodium hydroxide (2.5 mL) was added. The 
mixture was stirred at r.t per 24h. The ethanol was removed in vacuo. The residue was ice added 
and hydrochloric acid 10% solution added until pH 6. The obtained precipitate was filtered off, 
washed with cold water (3 x 10 mL) and dried.  Yield 48%. Mp >250 °C (EtOH). 1H NMR (DMSO-d6): 
δ 6.89 (d, J = 7.5 Hz, 2H, Ar), 7.04 (d, J = 15.5 Hz, 1H, CH), 7.55 (d, J = 7.5 Hz, 2H, Ar), 7.75 (s, 1H, Ar), 
7.99 (m, 2H, Ar), 8.16 (d, J = 15.5 Hz, 1H, CH), 10.30 (s, 1H, OH). 13C (DMSO-d6): δ 116.3, 117.6 (2C), 
119.4, 125.3, 126.2 (2C), 130.7, 131.3 (2C), 136.3, 141.2, 143.5, 144.7, 161.4, 169.8. IR (Nujol) 3345, 
3190, 1686, 1639, 1600 cm-1. m/z 281 (M + H)+. Anal. Calcd for C16H12N2O3: C, 68.56; H, 4.32; N, 9.99. 
Found: C, 68.50; H, 4.30; N, 10.03.
4.3. Biological assays
4.3.1. DPPH assay
The activity of the synthesized derivatives against DPPH• radical was tested following the Wang et 
al method [25] modified as previously reported [17]. The results are expressed as μmol TE/g 
corresponding to an inhibition of the radical equal to 50%, except for some compounds.
4.3.2. FRAP test
The FRAP antioxidant capacity of benzimidazoles was measured according to the method 
described previously [26], reading the absorbance of the reaction mixture at 593 nm. The values 
are expressed as μmol TE/g compound.
4.3.3. Oxygen Radical Absorbance Capacity (ORAC)
Peroxyl radical scavenging activity was measured based on a protocol previously reported and 
modified [27]. Phosphate buffer solution (pH 7.4) was used to prepare sample solutions and a series 
of Trolox solutions (40–240 μM) by diluting a 2 mM solution of Trolox. 25 μl of sample solution, 
Trolox dilution or phosphate buffer solution (pH 7.4) used as blank was placed in wells of a 96-well 
black microplate (VWR). Measurements of fluorescence were carried out at 37 °C and recorded at 
5 min intervals up 30 min after the addition of AAPH. The ORAC values were calculated according to 
the method of Cao et al. [28] and expressed as Trolox equivalents (μmol TE/μmol).
4.3.4. Evaluation of filtering parameters
The method followed is an adaptation of the official method for determining the value of SPF in 
vitro [29]. Solutions of the tested benzimidazoles were prepared in MeOH at a concentration of 
0.000034 (±0.0000033) M and the absorption spectra were recorded. To calculate the SPF value in 
vitro, the absorbance values obtained were transformed into transmittance values, using the 
equation below:
A( ) = Log[T( )]
The transmittance spectrum was elaborated with the SPF calculator software (version 2.1, 
Shimadzu, Milan, Italy) to obtain the values of SPF, UVA/UVB, UVAPF and λ critical.
4.3.5. Formulations
Formulation A and Formulation B, standard oil/water emulsions, were prepared for Oxisol and 
benzimidazole 15. Each phase, after adding the individual ingredients, was heated to a temperature 
between 60 and 70 ° C. At this point, below mechanical stirring, the oily phase was added to the 
aqueous phase. The selected compound was added in the subsequent cooling phase of the 
emulsion, kept constant agitation, to preserve it from possible thermal degradation. The emulsion, 
once cooled to 25 ° C, is stored in the refrigerator until the next day of analysis. The formulation 
compositions are the following:
Formulation A: Aqua, Ethylhexyl Stearate, Tribehenin PEG-20 Esters, Butyrospermum Parkii, Olea 
Europaea Oil Unsaponifiables, Oxisol or benzimidazole 15, Xanthan Gum, Caprylic/Capric 
Triglyceride, Cetearyl Alcohol, Dicaprylyl Carbonate.
Formulation B: Aqua, Cetearyl Alcohol, Tribehenin PEG-20 Esters, Butyrospermum Parkii, Olea 
Europaea Oil Unsaponifiables, Oxisol or benzimidazole 15, Xanthan Gum, Caprylic/Capric 
Triglyceride.
4.3.6. Franz cells apparatus
Cuprophan Regenerated cellulose from Medicell (London, UK), membrane thickness (11.5 µm ±} 
0,5µm), molecular weight cut off range (10,000 Da) was chosen as synthetic membrane employed 
in Franz diffusion cells experiments in this study. The effective diffusion area of the Franz cells was 
0.6 cm2 and receptor volume was 4.3 mL. Before being mounted on the diffusion cells, the 
membranes were conditioned with the receiving solution (DMSO). The membrane was positioned 
between the two compartments and the formulation (0.5 g) was placed in the donor compartment, 
in contact with the membrane. The aforementioned compartment was then sealed with Parafilm in 
order to avoid loss of formulation components. The thus prepared Franz cells were immersed in a 
thermostat bath to guarantee a surface temperature of the membrane of 37 ± 1 ° C, keeping the 
receiving solvent under continuous magnetic stirring. At each set time (after 30 minutes, 1 hour and 
then every hour thereafter up to 6 hours) using a glass syringe, 500 μl of sample were taken and 
replaced by 500 μl of fresh receiving medium, and the absorbance of the samples was measured 
using a UV-VIS spectrophotometer at the λmax. A calibration line and a release curve were built for 
each compound.
4.3.7. Growth inhibition assays 
Cell growth inhibition assays were carried out using two human cell lines, melanoma Colo38 [30, 31, 
17] and keratinocyte HaCat [31, 32], cells. Colo 38 cell line was maintained in RPMI 1640, 
supplemented with 10% fetal bovine serum (FBS), penicillin (100 Units mL-1), streptomycin (100 μg 
mL-1) and glutamine (2 mM) (complete medium); the pH of the medium was 7.2 and the incubation 
was performed at 37 °C in a 5% CO2 atmosphere. HaCat cell line were grown in DMEM medium 
(4.5g/L glucose) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin/streptomycin 
and 2 mM L-glutamine, in a 5% CO2 environment at 37°C. Benzimidazole derivatives were dissolved 
in MeOH/DMSO 10% to obtain 20mM stock solutions and diluted before cell treatment in MeOH 
100%. The tested benzimidazoles were added at serial dilutions to the cell cultures and incubated 
for 3 days. Cells were then harvested, suspended in physiological solution and counted with a Z2 
Coulter Counter (Coulter Electronics, Hialeah, FL, USA). The cell number/ml was determined as IC50 
after 3 days of culture, when untreated cells are in log phase of cell growth. Untreated cells were 
placed in every plate as negative control.
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 A small library of 2-arylbenzimidazole were synthetized
 Synthesized compounds were tested as antioxidants agents by DPPH, FRAP and ORAC assays
 The UV filtering power of benzimidazoles endowed with the best antioxidant profile was evaluated
 Compound 45 showed the best antioxidant and photoprotective properties
 Compound 45 selectively inhibited the growth of Colo-38 cell line at low micromolar concentration
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